# Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

> **NCT01973062** · PHASE2 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Primary Central Nervous System Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **RADIATION:** yttrium Y 90 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT01973062
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Funding Unavailable
- **Last updated:** 2020-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01973062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01973062, "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01973062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*